170 related articles for article (PubMed ID: 33420363)
1. Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance.
Yoshida K; Yokoi A; Sugiyama M; Oda S; Kitami K; Tamauchi S; Ikeda Y; Yoshikawa N; Nishino K; Niimi K; Suzuki S; Kikkawa F; Yokoi T; Kajiyama H
Oncogene; 2021 Feb; 40(7):1255-1268. PubMed ID: 33420363
[TBL] [Abstract][Full Text] [Related]
2. Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients.
Bagnoli M; De Cecco L; Granata A; Nicoletti R; Marchesi E; Alberti P; Valeri B; Libra M; Barbareschi M; Raspagliesi F; Mezzanzanica D; Canevari S
Oncotarget; 2011 Dec; 2(12):1265-78. PubMed ID: 22246208
[TBL] [Abstract][Full Text] [Related]
3. ChrXq27.3 miRNA cluster functions in cancer development.
Yoshida K; Yokoi A; Yamamoto Y; Kajiyama H
J Exp Clin Cancer Res; 2021 Mar; 40(1):112. PubMed ID: 33766100
[TBL] [Abstract][Full Text] [Related]
4. miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells.
Wang Y; Yan C; Qi J; Liu C; Yu J; Wang H
Mol Cell Biochem; 2022 Jan; 477(1):307-317. PubMed ID: 34716858
[TBL] [Abstract][Full Text] [Related]
5. Extracellular vesicles carrying miR-6836 derived from resistant tumor cells transfer cisplatin resistance of epithelial ovarian cancer via DLG2-YAP1 signaling pathway.
Zou Y; Zhao Z; Wang J; Ma L; Liu Y; Sun L; Song Y
Int J Biol Sci; 2023; 19(10):3099-3114. PubMed ID: 37416779
[No Abstract] [Full Text] [Related]
6. Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway.
Dai J; Wei R; Zhang P; Kong B
J Transl Med; 2019 Jun; 17(1):190. PubMed ID: 31171023
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
[TBL] [Abstract][Full Text] [Related]
8. miR-194-5p inhibits SLC40A1 expression to induce cisplatin resistance in ovarian cancer.
Wu J; Zhang L; Wu S; Yi X; Liu Z
Pathol Res Pract; 2020 Jul; 216(7):152979. PubMed ID: 32534701
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
12. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
13. MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition.
Cao L; Wan Q; Li F; Tang CE
BMB Rep; 2018 Sep; 51(9):456-461. PubMed ID: 30037365
[TBL] [Abstract][Full Text] [Related]
14. Loss of MiR-424-3p, not miR-424-5p, confers chemoresistance through targeting YAP1 in non-small cell lung cancer.
Zhang M; Zeng J; Zhao Z; Liu Z
Mol Carcinog; 2017 Mar; 56(3):821-832. PubMed ID: 27500472
[TBL] [Abstract][Full Text] [Related]
15. The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines.
Kazmierczak D; Jopek K; Sterzynska K; Nowicki M; Rucinski M; Januchowski R
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008952
[TBL] [Abstract][Full Text] [Related]
16. Preoperative serum microRNAs as potential prognostic biomarkers in ovarian clear cell carcinoma.
Suzuki K; Yokoi A; Yoshida K; Kato T; Ochiya T; Yamamoto Y; Kajiyama H
J Gynecol Oncol; 2023 May; 34(3):e34. PubMed ID: 36603851
[TBL] [Abstract][Full Text] [Related]
17. miR-509-3p enhances platinum drug sensitivity in ovarian cancer.
Niu L; Ni H; Hou Y; Du Q; Li H
Gene; 2019 Feb; 686():63-67. PubMed ID: 30408550
[TBL] [Abstract][Full Text] [Related]
18. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
19. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
20. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
